2626 Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis. (September 2015) - Guida, A.; Matias, M.; Albiges, L.; Derosa, L.; Loriot, Y.; Massard, C.; Fizazi, K.; Escudier, B.